Sign up to save your podcasts
Or
Share Disruptive Trends in Drug and Device Development, with Kymanox President Evan Edwards
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Disruptive Trends in Drug and Device Development, with Kymanox President Evan Edwards
In this episode of Life Science Solutions, Evan Edwards, President of Kymanox, explores the key trends shaping the life sciences industry in 2025. From groundbreaking advancements in cell and gene therapies to the rise of GLP-1 drugs and the essential scaling of CDMO operations, Evan highlights the innovations driving product development and commercialization.
Key Takeaways:
- Kymanox Growth: The company is expanding its capabilities, workforce, and global footprint, now employing nearly 300 people across the U.S. and Europe.
- Industry Trends:
- Cell and Gene Therapy: Emerging targeted treatments are transforming patient outcomes and delivery methods, including potential home-based solutions.
- GLP-1 Drugs: These revolutionary therapies are disrupting healthcare and driving rapid market growth.
- Manufacturing Challenges: A rising need for capacity to meet demand for both innovative and traditional therapies.
- Artificial Intelligence: Kymanox is leveraging AI responsibly to enhance drug discovery, manufacturing, and regulatory processes.
- Strategic Focus for 2025:
- Doubling down on core services like product development, engineering, and regulatory strategy.
- Expanding into strategic services like CMC, CQV, and human factors expertise.
- Supporting clients in reaching critical milestones efficiently, saving time and resources.
- The Hypervirtual Model: Acting as a trusted co-pilot, Kymanox partners with clients of all sizes, from startups to global pharma giants, to drive innovation and commercialization.
Resources and Links:
- Learn more about Kymanox: kymanox.com
- Connect with Kymanox on LinkedIn: Kymanox LinkedIn
About Kymanox:
Kymanox has proven, collaborative, end-to-end solutions that help bring life science products to the market – and keep them there. We are a global professional services organization that supports comprehensive drug development with integrated science, engineering, compliance (e.g., QA/RA), and technical project management. Our work across small and large molecules, medical devices, and combination products affords us a wholly unique advantage. With our diverse team of experts, Kymanox helps clients navigate commercialization challenges that arise throughout a product’s life cycle – from early development to post-market – with optimized safety, quality, efficacy, and accessibility. We strive to advance life science innovation through insightful solutions and collaboration…because patients deserve better. Kymanox was founded in 2004 and is headquartered in Morrisville, North Carolina USA. Kymanox is backed by WestView Capital Partners, a Boston-based growth equity firm. For more information, visit https://www.kymanox.com/.
Life Science Solutions is edited and produced by Earfluence.
View all episodes
By KymanoxIn this episode of Life Science Solutions, Evan Edwards, President of Kymanox, explores the key trends shaping the life sciences industry in 2025. From groundbreaking advancements in cell and gene therapies to the rise of GLP-1 drugs and the essential scaling of CDMO operations, Evan highlights the innovations driving product development and commercialization.
Key Takeaways:
- Kymanox Growth: The company is expanding its capabilities, workforce, and global footprint, now employing nearly 300 people across the U.S. and Europe.
- Industry Trends:
- Cell and Gene Therapy: Emerging targeted treatments are transforming patient outcomes and delivery methods, including potential home-based solutions.
- GLP-1 Drugs: These revolutionary therapies are disrupting healthcare and driving rapid market growth.
- Manufacturing Challenges: A rising need for capacity to meet demand for both innovative and traditional therapies.
- Artificial Intelligence: Kymanox is leveraging AI responsibly to enhance drug discovery, manufacturing, and regulatory processes.
- Strategic Focus for 2025:
- Doubling down on core services like product development, engineering, and regulatory strategy.
- Expanding into strategic services like CMC, CQV, and human factors expertise.
- Supporting clients in reaching critical milestones efficiently, saving time and resources.
- The Hypervirtual Model: Acting as a trusted co-pilot, Kymanox partners with clients of all sizes, from startups to global pharma giants, to drive innovation and commercialization.
Resources and Links:
- Learn more about Kymanox: kymanox.com
- Connect with Kymanox on LinkedIn: Kymanox LinkedIn
About Kymanox:
Kymanox has proven, collaborative, end-to-end solutions that help bring life science products to the market – and keep them there. We are a global professional services organization that supports comprehensive drug development with integrated science, engineering, compliance (e.g., QA/RA), and technical project management. Our work across small and large molecules, medical devices, and combination products affords us a wholly unique advantage. With our diverse team of experts, Kymanox helps clients navigate commercialization challenges that arise throughout a product’s life cycle – from early development to post-market – with optimized safety, quality, efficacy, and accessibility. We strive to advance life science innovation through insightful solutions and collaboration…because patients deserve better. Kymanox was founded in 2004 and is headquartered in Morrisville, North Carolina USA. Kymanox is backed by WestView Capital Partners, a Boston-based growth equity firm. For more information, visit https://www.kymanox.com/.
Life Science Solutions is edited and produced by Earfluence.